The stock is currently trading at an attractive valuation of 0.7x FY25E ABV and we value the stock at 0.9x FY25E ABV to arrive at a target price of Rs 150/share. The TP implies an upside of 21% from the CMP. We reiterate our BUY recommendation on the stock.